Leukemia, Myeloid, Acute: all 3,035 studies
Page 6 of 31. Open to participants first (746), then studies with results posted, then the rest; newest registration first within each.
- Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid LeukemiaRecruitingNCT05918198Phase 2
- Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCTRecruitingNCT05917405Phase 2
- Assessment of Geriatric Evaluations Impact on New AML GuidanceRecruitingNCT05909501
- Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete RemissionRecruitingNCT05909293Not applicable
- An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.RecruitingNCT05907057Phase 3
- Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLRecruitingNCT05904106Phase 2
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingNCT05886049Phase 1
- A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)Not yet recruitingNCT05876832Phase 3
- A Telehealth Advance Care Planning InterventionRecruitingNCT05875805Not applicable
- A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction FailureNot yet recruitingNCT05875649
- A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)RecruitingNCT05834244Phase 1
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCTRecruitingNCT05823714Phase 2
- Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid LeukemiaRecruitingNCT05807347Phase 2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingNCT05805098Phase 2/3
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- Frequency and Risk Factors of Acute Myeloid LeukemiaNot yet recruitingNCT05787951
- Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction StudiesRecruitingNCT05772559
- PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCTRecruitingNCT05772273Not applicable
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT05768932Phase 1
- A Study of ADCLEC.syn1 in People With Acute Myeloid LeukemiaRecruitingNCT05748197Phase 1
- Safety and Efficacy of Allogenic NK Cells in Combination With Chemotherapy in the Treatment of r/r AML After Allo-HSCTRecruitingNCT05744440Early Phase 1
- Expanded Access to ZiftomenibAvailableNCT05738538
- Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD ResultsRecruitingNCT05736978Phase 2
- A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid LeukemiaRecruitingNCT05736965Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingNCT05735184Phase 1
- A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic SyndromesRecruitingNCT05732103Phase 1/2
- UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05731219Phase 1
- Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT05726110Phase 3
- Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMRecruitingNCT05697510Phase 1
- Chidamide Prevents Recurrence of High-risk AML After Allo-HSCTRecruitingNCT05682755Phase 1/2
- Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic SyndromeEnrolling by invitationNCT05674539Phase 3
- CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid LeukemiaRecruitingNCT05672147Phase 1
- Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid LeukemiaRecruitingNCT05665075Phase 1
- Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AMLNot yet recruitingNCT05662904Phase 1
- A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced CancerRecruitingNCT05659732Phase 1
- CAV Regimen for R/R AMLRecruitingNCT05657639Phase 2
- A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLRecruitingNCT05641259Phase 1
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingNCT05636514Phase 1
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial TreatmentNot yet recruitingNCT05628623Phase 2
- Tazemetostat and Palbociclib With CPX-351for R/R AMLRecruitingNCT05627232Phase 1
- VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT05603884Phase 2
- First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult PatientsRecruitingNCT05601726Phase 1/2
- Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05597306Phase 1
- Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDSAvailableNCT05593185
- Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid MalignanciesRecruitingNCT05588154
- A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in ColombiaRecruitingNCT05587049
- HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AMLRecruitingNCT05586074Phase 3
- Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAMLRecruitingNCT05584761Phase 1/2
- Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid MalignanciesRecruitingNCT05583175Phase 2
- Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line TreatmentRecruitingNCT05580861Phase 1/2
- Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)RecruitingNCT05580601Phase 1/2
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingNCT05565105Phase 2
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
- Study of Management and Prognosis of Patients With Acute Myeloblastic Leukemia in Saint-Antoine HospitalNot yet recruitingNCT05558943
- CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AMLRecruitingNCT05558124Phase 1
- Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)Not yet recruitingNCT05554419Phase 2
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingNCT05554406Phase 2
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingNCT05554393Phase 2
- Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaRecruitingNCT05522192Phase 1/2
- Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid LeukemiaRecruitingNCT05519384Early Phase 1
- Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAMLRecruitingNCT05513131Phase 2
- Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05506332Phase 1
- Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid LeukemiaRecruitingNCT05504408
- Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AMLRecruitingNCT05503134Phase 1/2
- Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)RecruitingNCT05488132Phase 1/2
- Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AMLRecruitingNCT05477589Phase 3
- SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingNCT05445154Phase 1/2
- Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid LeukemiaRecruitingNCT05445011Phase 1
- Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)RecruitingNCT05444348Not applicable
- Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsRecruitingNCT05442216Phase 2
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell TransplantationRecruitingNCT05436418Phase 1/2
- TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05432401Early Phase 1
- Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML ProfilingRecruitingNCT05431257Phase 2
- Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCTRecruitingNCT05429632Phase 3
- AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First RemissionRecruitingNCT05404906Phase 2/3
- IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)RecruitingNCT05401097Phase 2
- Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled TrialRecruitingNCT05382390Phase 3
- A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)RecruitingNCT05360160Phase 1/2
- Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDSRecruitingNCT05350748
- Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDSRecruitingNCT05342584Phase 1
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruitingNCT05334069
- Long-Term Follow-up StudyEnrolling by invitationNCT05332054
- Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)RecruitingNCT05322850Phase 1/2
- Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid LeukemiaNot yet recruitingNCT05319249Phase 1/2
- Venetoclax to Augment Epigenetic Modification and ChemotherapyRecruitingNCT05317403Phase 1
- Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AMLRecruitingNCT05305859Phase 2
- Single-cell Dynamic Profiling in Adults With Newly Diagnosed Acute Myeloid Leukemia Treated With Intensive Chemotherapy. A THEMA Study"RecruitingNCT05304156
- Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia RelapseRecruitingNCT05270200Phase 1/2
- Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AMLRecruitingNCT05264883Phase 3
- Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAMLRecruitingNCT05262465Not applicable
- CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by GenomicsRecruitingNCT05260528Phase 2
- Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter StudyRecruitingNCT05258799Not applicable
- A Study of HYML-122 in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingNCT05241106Phase 2
- A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)RecruitingNCT05241093Phase 2
- Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid LeukemiaRecruitingNCT05237258Not applicable
- AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05211570Phase 1/2
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)RecruitingNCT05190471Phase 1